4.35
0.02 (0.46%)
| Previous Close | 4.33 |
| Open | 4.40 |
| Volume | 68,782 |
| Avg. Volume (3M) | 183,728 |
| Market Cap | 295,134,688 |
| Price / Sales | 3.98 |
| Price / Book | 4.85 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -98.51% |
| Operating Margin (TTM) | -90.20% |
| Diluted EPS (TTM) | -1.00 |
| Quarterly Revenue Growth (YOY) | 12.70% |
| Total Debt/Equity (MRQ) | 35.19% |
| Current Ratio (MRQ) | 3.11 |
| Operating Cash Flow (TTM) | -38.93 M |
| Levered Free Cash Flow (TTM) | -24.65 M |
| Return on Assets (TTM) | -24.41% |
| Return on Equity (TTM) | -60.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | SOPHiA GENETICS SA | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 6.53% |
| % Held by Institutions | 58.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Akre Capital Management Llc | 31 Dec 2025 | 3,719,140 |
| Alta Wealth Advisors Llc | 31 Dec 2025 | 1,409,160 |
| Bank Pictet & Cie (Europe) Ag | 31 Dec 2025 | 255,200 |
| 1492 Capital Management Llc | 31 Dec 2025 | 208,345 |
| 52 Weeks Range | ||
| Median | 7.00 (60.92%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 26 Jan 2026 | 7.00 (60.92%) | Buy | 5.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan |
| 07 Jan 2026 | Announcement | SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology |
| 12 Dec 2025 | Announcement | AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |